These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33377439)

  • 21. Assessment of the Level of Satisfaction and Unmet Data Needs for Specialty Drug Formulary Decisions in the United States.
    Choi Y; Navarro RP
    J Manag Care Spec Pharm; 2016 Apr; 22(4):368-75. PubMed ID: 27023690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.
    Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S34-S48. PubMed ID: 28535104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analyses using real-world data: an overview of the literature.
    Bowrin K; Briere JB; Levy P; Millier A; Clay E; Toumi M
    J Med Econ; 2019 Jun; 22(6):545-553. PubMed ID: 30816067
    [No Abstract]   [Full Text] [Related]  

  • 24. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
    Xing S; Batt K; Kuharic M; Bullano M; Caicedo J; Chakladar S; Markan R; Farahbakhshian S
    J Manag Care Spec Pharm; 2023 Jun; 29(6):626-634. PubMed ID: 37276033
    [No Abstract]   [Full Text] [Related]  

  • 26. The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis.
    Synnott PG; Bloudek LM; Sharaf R; Carlson JJ; Pearson SD
    J Manag Care Spec Pharm; 2020 Mar; 26(3):236-239. PubMed ID: 32105176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis.
    Siddiqui ZA; Dhumal T; Patel J; LeMasters T; Almony A; Kamal KM
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1350-1364. PubMed ID: 36427338
    [No Abstract]   [Full Text] [Related]  

  • 28. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
    Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
    J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
    [No Abstract]   [Full Text] [Related]  

  • 29. Real-world evidence use in assessments of cancer drugs by NICE.
    Bullement A; Podkonjak T; Robinson MJ; Benson E; Selby R; Hatswell AJ; Shields GE
    Int J Technol Assess Health Care; 2020 Jul; ():1-7. PubMed ID: 32646531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?
    Cohen JT; Silver MC; Ollendorf DA; Neumann PJ
    Value Health; 2019 Dec; 22(12):1396-1401. PubMed ID: 31806196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
    Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
    F1000Res; 2018; 7():111. PubMed ID: 30026923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease.
    Synnott PG; McQueen RB; Ollendorf DA; Campbell JD; Pearson SD
    J Manag Care Spec Pharm; 2020 Jun; 26(6):782-785. PubMed ID: 32463783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact.
    Brown JP; Douglas IJ; Hanif S; Thwaites RMA; Bate A
    Value Health; 2021 Sep; 24(9):1241-1244. PubMed ID: 34452702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
    Deverka PA; Douglas MP; Phillips KA
    Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks.
    Gressler LE; Marinac-Dabic D; Resnic FS; Williams S; Yang K; Weichold F; Avila-Tang E; Mack C; Coplan P; Panagiotou OA; Pappas G
    Ther Innov Regul Sci; 2024 Jul; ():. PubMed ID: 39060838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies.
    Radawski CA; Hammad TA; Colilla S; Coplan P; Hornbuckle K; Freeman E; Smith MY; Sobel RE; Bahri P; Arias AE; Bennett D
    Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1532-1539. PubMed ID: 33146901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-Centered Drug Approval: The Role of Patient Advocacy in the Drug Approval Process.
    Mattingly TJ; Simoni-Wastila L
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1078-1082. PubMed ID: 28944732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
    Malone DC; Brown M; Hurwitz JT; Peters L; Graff JS
    Value Health; 2018 Mar; 21(3):326-333. PubMed ID: 29566840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.